Increased serum S100B in never-medicated and medicated schizophrenic patients

Journal of Psychiatric Research

Volumn 44, Issue 16, 2010, Pages 1236-1240

  Zhang, Xiang Yang ^a,b,c   Xiu, Mei Hong ^b   Song, Cai ^d   Chen, Da Chun ^b   Wu, Gui Ying ^c   Haile, Colin N ^c   Kosten, Therese A ^c   Kosten, Thomas R ^c  

^a INSTITUTE OF PSYCHOLOGY   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

Antipsychotic treatment; Early psychosis; Psychopathology; S100B; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; PERPHENAZINE; PROTEIN S100B; RISPERIDONE; SULPIRIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CELL DAMAGE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIA CELL; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NERVE DEGENERATION; NEUROPATHOLOGY; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SMOKING;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; S100 PROTEINS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 78649527764     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.04.023     Document Type: Article

References (40)

1. Correll C.U., Malhotra A.K. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004, 174(4):477-489.
2. Donato R. S100: a multigenic family of calcium-modulated proteins of the EFhand type with intracellular and extracellular functional roles. The International Journal of Biochemistry & Cell Biology 2001, 33:637-668.
3. Farkas N., Lendeckel U., Dobrowolny H., Funke S., Steiner J., Keilhoff G., et al. Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World Journal of Biological Psychiatry 2010, 11(3):193-203.
4. Garver D.L., Holcomb J.A., Christensen J.D. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. International Journal of Neuropsychopharmacology 2008, 11:49-61.
5. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Gonçalves C.A., Tort A.B., et al. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophrenia Research 2000, 43:91-95.
6. Holtkamp K., Buhren K., Ponath G., von Eiff C., Herpertz-Dahlmann B., Hebebrand J., et al. Serum levels of S100B are decreased in chronic starvation and normalize with weight gain. Journal of Neural Transmission 2008, 115:937-940.
7. Lamers K.J., van Engelen B.G., Gabreels F.J., Hommes O.R., Borm G.F., Wevers R.A. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurologica Scandinavica 1995, 92:247-251.
8. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., et al. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. Journal of Psychiatric Research 2007, 41:36-42.
9. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochemical and Biophysical Research Communications 2005, 328(1):335-341.
10. Nygaard O., Langbakk B., Romner B. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clinical Chemistry 1997, 43:541-543.
11. Pedersen A., Diedrich M., Kaestner F., Koelkebeck K., Ohrmann P., Ponath G., et al. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1789-1792.
12. Qi L.Y., Xiu M.H., Chen da C., Wang F., Kosten T.A., Kosten T.R., et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neuroscience Letters 2009, 462(2):113-117.
13. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry 2001, 6:445-449.
14. Rothermundt M., Peters M., Prehn J.H., Arolt V. S100B in brain damage and neurodegeneration. Microscopy Research and Technique 2003, 60:614-632.
15. Rothermundt M., Ponath G., Glaser T., Hetzel G., Arolt V. S100B serum levels and long term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004, 29:1004-1011.
16. Rothermundt M., Falkai P., Ponath G., Abel S., Bürkle H., Diedrich M., et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Molecular Psychiatry 2004, 9:897-899.
17. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 30:361-364.
18. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative/antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1164-1169.
19. Scaccianoce S., Del Bianco P., Pannitteri G., Passarelli F. Relationship between stress and circulating levels of S100B protein. Brain Research 2004, 1004:208-211.
20. Schafer B.W., Heizmann C.W. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends in Biochemical Sciences 1996, 21:134-140.
21. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophrenia Research 2005, 80:305-313.
22. Schmitt A., Steyskal C., Bernstein H.G., Schneider-Axmann T., Parlapani E., Schaeffer E.L., et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathologica 2009, 117:395-407.
23. Schroeter M.L., Mertsch K., Giese H., Müller S., Sporbert A., Hickel B., et al. Astrocytes enhance radical defence in capillary endothelial cells constituting the blood-brain barrier. FEBS Letters 1999, 49:241-244.
24. Schroeter M.L., Abdul-Khaliq H., Frühauf S., Höhne R., Schick G., Diefenbacher A., et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophrenia Research 2003, (62):231-236.
25. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - original research and meta-analysis. Psychiatry Research 2009, 167:66-72.
26. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Molecular Psychiatry 2009, 14:235-237.
27. Sen J., Belli A. S100B in neuropathologic states: the CRP of the brain?. Journal of Neuroscience Research 2007, 85:1373-1380.
28. Steiner J., Bielau H., Bernstein H.G., Bogerts B., Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. The Journal of Neurology, Neurosurgery, and Psychiatry 2006, 77:1284-1287.
29. Steiner J., Bernstein H.G., Bielau H., Berndt A., Brisch R., Mawrin C., et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neuroscience 2007, 8:2.
30. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., et al. S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation. Neuroscience 2008, 154:496-503.
31. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., et al. Bogerts, B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. Journal of Psychiatric Research 2008, 42:868-876.
32. Steiner J., Schiltz K., Walter M., Wunderlich M.T., Keilhoff G., Brisch R., et al. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010, 35:321-324.
33. Steiner J., Walter M., Guest P., Myint A.M., Schiltz K., Panteli B., et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Molecular Psychiatry 2010, 15(1):3-4.
34. Tan Y., Luo X., Yang F., Zhang W., Wang Z., Zou Y., et al. Elevated serum S100B protein in first-episode drug-naïve Chinese patients with schizophrenia. Schizophrenia Research 2010 Feb 16, [Epub ahead of print].
35. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362(9386):798-805.
36. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophrenia Research 2004, 67:269-275.
37. Uranova N.A., Vostrikov V.M., Vikhreva O.V., Zimina I.S., Kolomeets N.S., Orlovskaya D.D. The role of oligodendrocyte pathology in schizophrenia. International Journal of Neuropsychopharmacology 2007, 10(4):537-545.
38. van Beveren N.J., van der Spelt J.J., de Haan L., Fekkes D. Schizophrenia-associated neural growth factors in peripheral blood. A review. European Neuropsychopharmacology 2006, 16:469-480.
39. Wiesmann M., Missler U., Hagenstrom H., Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochirurgica 1997, 139:1155-1160.
40. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biological Psychiatry 1999, 45:1508-1511.